Zdrowie i gospodarka · 26/01/2018

FDA Extends Comment Period for Draft Guidance on Dual 510(k) and CLIA Waiver

The FDA is extending the comment period for its draft guidance on dual 510(k) and CLIA waiver by application studies, in response to a request for an extension, to allow industry and FDA staff more time to submit comments.